Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
19. Juli 2024 09:01 ET
|
Altamira Therapeutics Ltd
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Study shows significant reduction in aorta dilation, delayed rupture and lower mortality in established animal model of abdominal aortic...
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)
30. April 2024 08:05 ET
|
Senti Biosciences, Inc.
Senti Bio today announced the publication of preclinical data that supports the design of the Phase 1 clinical trial of SENTI-202.
Wave Life Sciences Announces Upcoming Presentations at MDA Conference that Highlight Best-in-Class Potential for WVE-N531 in Duchenne Muscular Dystrophy
27. Februar 2024 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentations include data for WVE-N531 that provide first clinical evidence of a potential therapeutic for DMD accessing satellite cells, which are important for potential muscle regeneration ...
Anti-Cancer Drugs Publishes Preclinical Data Demonstrating the Broad Antineoplastic Activity of Panavance’s Misetionamide (GP-2250)
01. Februar 2024 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on normal cells Misetionamide reduces energy...
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
29. Januar 2024 07:03 ET
|
Unicycive Therapeutics, Inc.
LOS ALTOS, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the...
International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma
21. November 2023 07:07 ET
|
Panavance Therapeutics Inc.
Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for approximately 50% of all melanomas BERWYN, PA, Nov. ...
Journal of Cellular and Molecular Medicine Publishes Preclinical Data of Panavance’s GP-2250 to treat Pancreatic Cancer
12. September 2023 07:07 ET
|
Panavance Therapeutics Inc.
Results showed antineoplastic activity in pancreatic tumor cell lines Metabolic and transcriptional findings demonstrate a molecular basis to reduce tumor cell proliferation and induce apoptotic cell...
GRI Bio Presents Encouraging Preclinical Data Indicating Oral Administration of GRI-0803 Inhibited Lupus Nephritis and Significantly Improved Overall Survival in Animal Models
07. August 2023 08:35 ET
|
GRI Bio, Inc.
Data presented at The Autoimmunity Conference hosted by the Federation of American Societies for Experimental Biology (FASEB) GRI-0803 in development with an initial focus on the treatment...
Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv
07. August 2023 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
14. Juni 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...